{"id":"sitaxentan","_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=SITAXENTAN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:22:13.013978+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T02:22:27.131896+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:22:19.990720+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SITAXENTAN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:22:20.713388+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Endothelin receptor, ET-A/ET-B antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:22:21.291869+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2105740/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:22:21.191734+00:00"}},"_dailymed":null,"aiSummary":"Sitaxentan is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, leveraging its unique mechanism of action. The primary risk is the potential increase in competition following the patent expiry in 2028.","_scrapedAt":"2026-03-28T00:34:26.073Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:22:27.132241+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT01347216","phase":"","title":"COMPERA / COMPERA-KIDS","status":"RECRUITING","sponsor":"Technische Universität Dresden","startDate":"2007-07-01","conditions":"Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension (PH)","enrollment":14000},{"nctId":"NCT00817037","phase":"PHASE2","title":"Sitaxsentan in Proteinuric Chronic Kidney Disease","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2007-07-14","conditions":"Chronic Kidney Disease, Proteinuria, Blood Pressure","enrollment":27},{"nctId":"NCT00810732","phase":"PHASE2","title":"Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-05-09","conditions":"Chronic Kidney Disease","enrollment":27},{"nctId":"NCT00303498","phase":"PHASE2","title":"A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-03-27","conditions":"Diastolic Heart Failure","enrollment":200},{"nctId":"NCT00838383","phase":"PHASE2","title":"Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-08-10","conditions":"Cardiac Surgery Subjects, Subjects Undergoing CABG and/or Cardiac Valve Replacement","enrollment":29},{"nctId":"NCT00593905","phase":"","title":"Pharmacogenomics in Pulmonary Arterial Hypertension","status":"WITHDRAWN","sponsor":"West Penn Allegheny Health System","startDate":"2005-07","conditions":"Pulmonary Arterial Hypertension, Pulmonary Hypertension, PAH WHO Group I","enrollment":""},{"nctId":"NCT01445873","phase":"","title":"Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-12-01","conditions":"Pulmonary Arterial Hypertension","enrollment":36},{"nctId":"NCT00796510","phase":"PHASE3","title":"Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety","status":"TERMINATED","sponsor":"Pfizer","startDate":"2010-07","conditions":"Pulmonary Arterial Hypertension, Pulmonary Hypertension","enrollment":3},{"nctId":"NCT00744211","phase":"NA","title":"Proteolytic Enzyme Induction Within the Human Myocardial Interstitium","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2008-07","conditions":"Heart Disease","enrollment":29},{"nctId":"NCT01100736","phase":"EARLY_PHASE1","title":"Role of Endothelin-A (ETA) and Endothelin-B (ETB) Receptors in the Vasodilatory Response to Endothelin-3 (ET-3)","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2009-01","conditions":"Pulmonary Arterial Hypertension, Vasodilation, Vasoconstriction","enrollment":10},{"nctId":"NCT00796666","phase":"PHASE3","title":"Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil","status":"TERMINATED","sponsor":"Pfizer","startDate":"2009-05","conditions":"Pulmonary Arterial Hypertension, Pulmonary Hypertension","enrollment":131},{"nctId":"NCT00795639","phase":"PHASE3","title":"Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)","status":"TERMINATED","sponsor":"Pfizer","startDate":"2008-12","conditions":"Pulmonary Arterial Hypertension, Pulmonary Hypertension","enrollment":183},{"nctId":"NCT01251835","phase":"PHASE1","title":"Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2010-12","conditions":"Pulmonary Arterial Hypertension","enrollment":""},{"nctId":"NCT01251848","phase":"PHASE1","title":"Drug Interaction Between Ritonavir And Sitaxsentan","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2011-01","conditions":"Pulmonary Arterial Hypertension","enrollment":""},{"nctId":"NCT01281371","phase":"","title":"Observation Study of the Medication Switch at Patients Treated With Sitaxentan to a Regime Without Sitaxentan","status":"COMPLETED","sponsor":"Heidelberg University","startDate":"2011-01","conditions":"Hypertension, Pulmonary","enrollment":9},{"nctId":"NCT01050491","phase":"PHASE2","title":"Study on the Effects of Sitaxsentan on Airway Remodeling in Patients With Severe Asthma","status":"TERMINATED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-11","conditions":"Effect of Sitaxsentan on Airway Remodeling in Severe Asthma","enrollment":17},{"nctId":"NCT00811018","phase":"PHASE3","title":"A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension","status":"TERMINATED","sponsor":"Pfizer","startDate":"2003-03","conditions":"Pulmonary Arterial Hypertension","enrollment":1192},{"nctId":"NCT01244620","phase":"PHASE1","title":"A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses","status":"TERMINATED","sponsor":"Pfizer","startDate":"2010-11","conditions":"Pulmonary Arterial Hypertension","enrollment":16},{"nctId":"NCT00995566","phase":"","title":"A Non-Interventional, Patient Registry For The Collection Of Pre-Defined Safety Data In Patients Prescribed Thelin","status":"TERMINATED","sponsor":"Pfizer","startDate":"2010-04","conditions":"Pulmonary Arterial Hypertension","enrollment":54},{"nctId":"NCT01210443","phase":"PHASE3","title":"Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients","status":"TERMINATED","sponsor":"Pfizer","startDate":"2010-11","conditions":"Hypertension, Pulmonary","enrollment":2},{"nctId":"NCT01204853","phase":"PHASE3","title":"A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients","status":"TERMINATED","sponsor":"Pfizer","startDate":"2010-08","conditions":"Hypertension, Pulmonary","enrollment":2},{"nctId":"NCT00981968","phase":"PHASE1","title":"Phase 1, Single and Multiple Doses Study of Sitaxentan in Japanese and Western Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-09","conditions":"Healthy","enrollment":22},{"nctId":"NCT00080457","phase":"PHASE3","title":"Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Encysive Pharmaceuticals","startDate":"2003-05","conditions":"Pulmonary Hypertension","enrollment":240},{"nctId":"NCT00034307","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Sitaxsentan in the Treatment of Pulmonary Arterial Hypertension","status":"UNKNOWN","sponsor":"ICOS-Texas Biotechnology","startDate":"","conditions":"Pulmonary Hypertension","enrollment":180}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL2105740"},"_approvalHistory":[],"publicationCount":90,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"withdrawn","brandName":"SITAXENTAN","genericName":"SITAXENTAN","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"2006","enrichmentLevel":3,"visitCount":2,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:22:27.132241+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}